(Q33162724)

23 July 2017

Safety of human papillomavirus vaccines: a review. (English)

1 reference

23 July 2017

1 reference

3

Melina Georgousakis

1 reference

23 July 2017

4

Julia M L Brotherton

1 reference

23 July 2017

Kristine K Macartney

1

1 reference

PubMed ID

23637071

23 July 2017

Clayton Chiu

series ordinal

2

1 reference

23 July 2017

1 June 2013

1 reference

23 July 2017

1 reference

23 July 2017

36

1 reference

23 July 2017

6

1 reference

23 July 2017

393-412

1 reference

https://scigraph.springernature.com/pub.10.1007/s40264-013-0039-5

23 July 2017

0 references

cites work

Human papillomavirus and cervical cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Beyond cervical cancer: burden of other HPV-related cancers among men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

The epidemiology of genital human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Global epidemiology of sexually transmitted diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Currently approved prophylactic HPV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

The Brighton Collaboration: enhancing comparability of vaccine safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Quadrivalent HPV vaccine administered to women who became pregnant during trials did not appear to adversely affect pregnancy outcome; however, use during pregnancy is not recommended

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Reported paediatric adverse drug reactions in the UK 2000-2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Anaphylaxis following quadrivalent human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Human papilloma virus vaccines: Current scenario

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

CNS demyelination and quadrivalent HPV vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

"I just signed": Factors influencing decision-making for school-based HPV vaccination of adolescent girls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

The role of the Immunisation Adverse Events Clinic at The Children's Hospital at Westmead

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Reported adverse events in young women following quadrivalent human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

The risk of immune thrombocytopenic purpura after vaccination in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Safety of quadrivalent human papillomavirus vaccine administered routinely to females

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Autoimmune diseases after adolescent or adult immunization: what should we expect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Post-licensure monitoring of HPV vaccine in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

NSW annual report describing adverse events following immunisation, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

NSW annual report describing adverse events following immunisation, 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Aluminum granuloma after administration of the quadrivalent human papillomavirus vaccine. Report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

HPV vaccine: a cornerstone of female health a possible cause of ADEM?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Acute disseminated encephalomyelitis following vaccination against human papilloma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

21 January 2018

A catastrophic failure.

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Demyelinating disease and polyvalent human papilloma virus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Ampiginous choroiditis following quadrivalent human papilloma virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Opsoclonus Myoclonus after human papilloma virus vaccine in a pediatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Systemic lupus erythematosus following HPV immunization or infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

The India HPV-vaccine suspension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0039-5

An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in health

21 January 2018

1 reference

12 December 2020

Quadrivalent Human Papillomavirus recombinant vaccine associated lipoatrophy

1 reference

12 December 2020

Postural tachycardia syndrome after vaccination with Gardasil

1 reference

12 December 2020

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials

1 reference

12 December 2020

Brachial plexus neuritis following HPV vaccination

1 reference

12 December 2020

Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy

1 reference

12 December 2020

Withdrawal of rotavirus vaccine recommendation

1 reference

12 December 2020

Syncope and seizures following human papillomavirus vaccination: a retrospective case series.

1 reference

12 December 2020

Global Advisory Committee on Vaccine Safety, 17-18 December 2008

1 reference

12 December 2020

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

1 reference

12 December 2020

Complex regional pain syndrome following immunisation

1 reference

12 December 2020

Telogen effluvium following bivalent human papillomavirus vaccine administration: a report of two cases

1 reference

12 December 2020

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years

1 reference

12 December 2020

Immune thrombocytopenic purpura following human papillomavirus vaccination

1 reference

12 December 2020

FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Postlicensure safety evaluation of human papilloma virus vaccines

1 reference

12 December 2020

Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011

1 reference

12 December 2020

Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls

1 reference

12 December 2020

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of

1 reference

12 December 2020

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis

1 reference

12 December 2020

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years

1 reference

12 December 2020

Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women

1 reference

12 December 2020

Pancreatitis following human papillomavirus vaccination

1 reference

12 December 2020

Mass psychogenic response to human papillomavirus vaccination.

1 reference

12 December 2020

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

1 reference

12 December 2020

The Manitoba human papillomavirus vaccine surveillance and evaluation system.

1 reference

12 December 2020

Human papilloma virus vaccination in Nepal: an initial experience in Nepal.

1 reference

12 December 2020

Update on Human Papillomavirus (HPV) Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) †

1 reference

12 December 2020

Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia.

1 reference

12 December 2020

Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Advisory Committee on Causality Assessment

1 reference

12 December 2020

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines

1 reference

12 December 2020

Syncope after vaccination--United States, January 2005-July 2007.

1 reference

12 December 2020

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

1 reference

12 December 2020

Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: public health implications for the region

1 reference

12 December 2020

Anaphylaxis as an adverse event following immunisation in the UK and Ireland

1 reference

12 December 2020

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

12 December 2020

10.1007/S40264-013-0039-5

Identifiers

DOI

1 reference

PubMed ID

23637071

Dimensions Publication ID

23 July 2017

0 references

1 reference

PubMed ID

23637071